These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28800947)

  • 61. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.
    de Boysson H; Boutemy J; Creveuil C; Ollivier Y; Letellier P; Pagnoux C; Bienvenu B
    Semin Arthritis Rheum; 2013 Aug; 43(1):105-12. PubMed ID: 23453684
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.
    Schönau V; Roth J; Tascilar K; Corte G; Manger B; Rech J; Schmidt D; Cavallaro A; Uder M; Crescentini F; Boiardi L; Casali M; Spaggiari L; Galli E; Kuwert T; Versari A; Salvarani C; Schett G; Muratore F
    Rheumatology (Oxford); 2021 Aug; 60(8):3851-3861. PubMed ID: 33831144
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Large-vessel giant cell arteritis: diagnosis, monitoring and management.
    Koster MJ; Matteson EL; Warrington KJ
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii32-ii42. PubMed ID: 29982778
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ustekinumab for the Treatment of Giant Cell Arteritis.
    Matza MA; Fernandes AD; Stone JH; Unizony SH
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):893-897. PubMed ID: 32248659
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment and outcomes of large vessel arteritis.
    Borg FA; Dasgupta B
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):325-37. PubMed ID: 19508941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Treatment of giant cell arteritis].
    Samson M; Greigert H; Bonnotte B
    Rev Prat; 2023 Apr; 73(4):395-399. PubMed ID: 37289152
    [TBL] [Abstract][Full Text] [Related]  

  • 69. My Treatment Approach to Giant Cell Arteritis.
    Garvey TD; Koster MJ; Warrington KJ
    Mayo Clin Proc; 2021 Jun; 96(6):1530-1545. PubMed ID: 34088416
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Giant-cell arteritis of the female genital tract associated with occult temporal arteritis and FDG-PET evidence of large-vessel vasculitis.
    Bajocchi G; Zamorani G; Cavazza A; Pipitone N; Versari A; Boiardi L; Salvarani C
    Clin Exp Rheumatol; 2007; 25(1 Suppl 44):S36-9. PubMed ID: 17428363
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review].
    Kieffer P; Hinschberger O; Ciobanu E; Jaeger-Bizet F; Drabo A; Mostoufizadeh T; Martzolff L
    Rev Med Interne; 2014 Jan; 35(1):56-9. PubMed ID: 24075627
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neuro-Ophthalmologic Complications of Giant Cell Arteritis: Diagnosis and Treatment.
    Fein AS; Ko MW
    Semin Neurol; 2019 Dec; 39(6):673-681. PubMed ID: 31847038
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.
    Ly KH; Dalmay F; Gondran G; Palat S; Bezanahary H; Cypierre A; Fauchais AL; Liozon E
    Medicine (Baltimore); 2016 Oct; 95(42):e4974. PubMed ID: 27759628
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of Giant Cell Arteritis (GCA).
    Régent A; Mouthon L
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407411
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Epidemiology and pathophysiology of giant cell arteritis].
    Greigert H; Bonnotte B; Samson M
    Rev Prat; 2023 Apr; 73(4):380-386. PubMed ID: 37289150
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Treatment of giant cell arteritis].
    Sailler L; Pugnet G; Bienvenu B
    Rev Med Interne; 2013 Jul; 34(7):431-7. PubMed ID: 23562185
    [TBL] [Abstract][Full Text] [Related]  

  • 77. How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis.
    Buttgereit F; Palmowski A
    Joint Bone Spine; 2022 Jan; 89(1):105285. PubMed ID: 34601110
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interleukin-1 blockade in refractory giant cell arteritis.
    Ly KH; Stirnemann J; Liozon E; Michel M; Fain O; Fauchais AL
    Joint Bone Spine; 2014 Jan; 81(1):76-8. PubMed ID: 23890680
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of toll like receptors in giant cell arteritis.
    O'Neill L; Molloy ES
    Rheumatology (Oxford); 2016 Nov; 55(11):1921-1931. PubMed ID: 26893518
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vision loss in patients with giant cell arteritis treated with tocilizumab.
    Amsler J; Kysela I; Tappeiner C; Seitz L; Christ L; Scholz G; Stalder O; Kollert F; Reichenbach S; Villiger PM
    Arthritis Res Ther; 2021 Mar; 23(1):92. PubMed ID: 33752737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.